http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Correlation between fetal aneuploidy and indications for non-invasive prenatal tests
( Jihye Koh ),( Jae-yoon Shim ),( Joohee Lee ),( Mi-young Lee ),( Hye-sung Won ),( Pil-ryang Lee ) 대한산부인과학회 2018 대한산부인과학회 학술대회 Vol.104 No.-
Objective: To determine the prevalence of fetal aneuploidy in accordance with the indications for a non-invasive prenatal test (NIPT). Methods: We retrospectively analyzed 415 cases involving patients who underwent NIPT between December 2016 and June 2018 at a single tertiary care center owing to maternal old age, positive serum screening test, abnormal pre-natal ultrasonography findings, previous history of fetal aneuploidy, abnormal parental karyotype, or substitution of serum screening test. The cases were classified based on the indications listed above as having individual or multiple indications. A single company conducted the tests. Results: The primary reason for NIPT was maternal old age (54.8%) followed by positive quad test results (20.2%), abnormal ultrasonography findings (14.8%), substitution of serum screening test (7.8%), previously affected pregnancy (1.9%), and abnormal parental karyotype (0.5%). Among the 415 cases, 11 were deemed high risk for fetal aneuploidy, including trisomy-21 (n=5), trisomy-18 (n=4) and trisomy-13 (n=2). Among the 11 cases grouped as high risk, ten cases of aneuploidy were identified with one case being a false-positive. Abnormal fetal ultrasonography findings were noted in all cases in the high-risk group. Nine cases (81%) were associated with advanced maternal age. A positive quad test was reported in two cases (18%). Conclusion: Among the various indications for NIPT, abnormal fetal ultrasonography findings could be helpful in predicting fetal aneuploidy.
( Jihye Koh ),( Jin Hoon Chung ),( Mi-young Lee ),( Hye-sung Won ),( Pil-ryang Lee ) 대한산부인과학회 2020 대한산부인과학회 학술대회 Vol.106 No.-
Objective: To assess indications of antiviral agents for mothers with hepatitis B virus (HBV) infection and investigate perinatal outcomes according to its applications. Methods: This was a retrospective study in pregnant women with HBV infection who received tenofovirs as antiviral therapy during the antenatal period between 2015 and 2019 at Asan Medical Center (AMC). Maternal serum HBV DNA level and HBeAg positivity were investigated to evaluate disease activity during perinatal periods. Applications of antiviral agents were assessed by the start timing, continuity, and purpose. As a perinatal outcome, whether neonates had HBV vaccination and hepatitis B immunoglobulin (HIBIG) prophylaxis were investigated. Mother-to-child transmission of HBV was also inspected. All data were evaluated by reviewing the patients’ medical records. Results: Forty-three pregnant women received tenofovir during pregnancy, of whom 4 had a twin pregnancy, and 47 neonates were delivered at AMC. The median gestational age at birth was 38.3 weeks (range, 30.6-40.3) and the median birth weight was 3323g (range, 1480-4090). All neonate had HBV vaccination and HIBIG after birth. Among 48 neonates, 50% (23/47) neonates successfully developed anti-HBs antibodies after HBV vaccine completion, but 34% (16/47) did not undergo the serum tests for HBsAg and anti-HB antibodies at AMC. No cases of vertical infection were reported over at least 2 months. Of the 39 women who underwent serum tests and follow-up at AMC, 46% (18/39) received the antiviral agent before pregnancy and continued the therapy and 20% (8/39) who discontinued the therapy because of pregnancy resumed it because of elevated alanine aminotransferase level. The median HBV-DNA level at the time of administration was 9.45x107 copies/mL (range, 4.6x102-9.8x108). Of the patients in the prophylactic group, 20% (8/39) never received the antiviral agent before pregnancy. The median HBV-DNA level at the time of administration was 1.45□108 copies/mL (range, 3.7×105-2.6×108 copies/mL). No adverse drug reactions were observed. Conclusion: During pregnancy, tenofovir therapy is safe, with no adverse side effects on mothers. With neonatal HBV vaccination and HIBIG administration, administration of the antiviral agent to mothers with HBV infection is important to prevent vertical transmission.
Koh, Joonyoung,Kim, Jihye,Shin, Jung H.,Lee, Wonhee American Institute of Physics 2014 Applied Physics Letters Vol.105 No.11
<P>Inertial microfluidics utilizes fluid inertia from high flow velocity to manipulate particles and fluids in 3D. Acquiring a 3D information of particle positions and complex flow patterns within microfluidic devices requires 3D imaging techniques such as confocal microscopy, which are often expensive and slow. Here, we report on a prism-mirror-embedded microfluidic device that allows simultaneous imaging of the top and side view of the microchannel for a high-speed, low-cost 3D imaging. The microprism mirrors are fabricated and integrated into a microfluidic system using conventional microfabrication techniques including wet etch and soft lithography. This inexpensive high quality prism mirror provides a highly reflective, smooth mirror surface with precise 45 degrees reflection angle, enabling 3D measurement of inertial migration of microparticles in a rectangular channel at speeds in excess of 10 000 frame/s. (C) 2014 AIP Publishing LLC.</P>
Jihye Kim,Wonseok Kang,Dong Hyun Sinn,Geum-Youn Gwak,Yong-Han Paik,Moon Seok Choi,Joon Hyeok Lee,Kwang Cheol Koh,Seung Woon Paik 대한간학회 2020 Clinical and Molecular Hepatology(대한간학회지) Vol.26 No.4
Background/Aims: Although hepatocellular carcinoma (HCC) is notorious for its high recurrence rate, some patients do not experience recurrence for more than 5 years after resection or radiofrequency ablation for early-stage HCC. For those with five recurrence-free period, the risk of HCC recurrence within the next 5 years remains unknown. Methods: A total of 1,451 consecutive patients (median, 55 years old; males, 79.0%; hepatitis B virus-related, 79.3%) with good liver function (Child-Pugh class A) diagnosed with early-stage HCC by Barcelona Clinic Liver Cancer Staging and received radiofrequency ablation or resection as an initial treatment between 2005 and 2010 were analyzed. Results: During a median follow-up period of 8.1 years, 961 patients (66.2%) experienced HCC recurrence. The cumulative recurrence rates increased to 39.7%, 60.3%, and 71.0% at 2, 5, and 10 years, respectively, and did not reach a plateau. Five years after HCC diagnosis, 487 patients were alive without experiencing a recurrence. Among them, during a median of 3.9 additional years of follow-up (range, 0.1–9.0 years), 127 patients (26.1%) experienced recurrence. The next 5-year cumulative recurrence rate (5–10 years from initial diagnosis) was 27.0%. Male sex, higher fibrosis-4 scores, and alpha-fetoprotein levels at 5 years were associated with later HCC recurrence among patients who did not experience recurrence for more than 5 years. Conclusions: The HCC recurrence rate following 5 recurrence-free years after HCC treatment was high, indicating that HCC patients warrant continued HCC surveillance, even after 5 recurrence-free years.
( Jihye Kim ),( Wonseok Kang ),( Dong Hyun Sinn ),( Geum-youn Gwak ),( Yong-han Paik ),( Moon Seok Choi ),( Joon Hyeok Lee ),( Kwang Cheol Koh ),( Seung Woon Paik ) 대한내과학회 2020 The Korean Journal of Internal Medicine Vol.35 No.1
Background/Aims: We systematically evaluated the clinical characteristics, prevalence of cirrhosis, and mode of detection in virus-unrelated (non-B non-C, NBNC) hepatocellular carcinoma (HCC) patients in Korea. Methods: A total of 447 consecutive treatment-naïve NBNC-HCC adult patients who were registered at the Samsung Medical Center HCC registry in Korea from 2010 to 2013 were analyzed. NBNC was defined as negative hepatitis B surface antigen and negative anti-hepatitis C virus antibody. Presence of cirrhosis was determined based on histological, radiological, endoscopic, and serologic results. Mode of detection was classified as either under surveillance, incidental, or symptomatic. Results: Heavy alcohol use was the most common potential etiology in NBNC-HCC (NBNC-A, alcohol) (59.7%). Ten patients had other identif iable causes (NBNC-O, other identifiable cause) such as autoimmune hepatitis. The rest (38.0%) had no-identifiable cause (NBNC-NA-NO, non-alcohol, no-other identifiable cause). In NBNC-NA-NO group, 83.5% (96/115) of patients with available hepatitis B core immunoglobulin G antibody (HBcIgG) showed HBcIgG positivity, and 80.6% (137/170) had metabolic risk factors (diabetes, obesity, hypertension, and/ or dyslipidemia). Cirrhosis was present in 90.0%, 70.4%, and 60.0% of NBNC-O, NBNC-A, and NBNC-NA-NO patients, respectively. The proportion of patients diagnosed under surveillance was 25.5% across all patients, with specific proportions being 80.0%, 27.7%, and 18.8% for NBNC-O, NBNC-A, and NBNC-NA-NO, respectively. Conclusions: Among NBNC-HCC patients, heavy alcohol use or any other identifiable cause was not found in 38.0%. These NBNC-NA-NO HCC patients showed a high prevalence of HBcIgG positivity and metabolic risk factors, suggesting that prior hepatitis B virus infection and metabolic risk factors may be major contributing factors in the hepatocarcinogenesis in NBNC-NA-NO patients.